Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome

References

• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491.
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721. e4
   PubMed Web of Science ®Google Scholar
• Peery AF, Crockett SD, Barritt AS, et al Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149(7):1731–1741.
   PubMed Web of Science ®Google Scholar
• Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023–1034.
   PubMed Web of Science ®Google Scholar
• Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103(5):1229–1239. quiz 1240
   PubMed Web of Science ®Google Scholar
• Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949–958.
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Hebden J, Campbell E, et al Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol. 2006;101(6):1288–1294.
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46(4):421–431.
   PubMed Web of Science ®Google Scholar
• Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163–173.
   PubMed Web of Science ®Google Scholar
• Kuiken SD, Lindeboom R, Tytgat GN, et al. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(2):157–164.
   PubMed Web of Science ®Google Scholar
• Ringel-Kulka T, Choi CH, Temas D, et al Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol. 2015;110(9):1339–1346.
   PubMed Web of Science ®Google Scholar
• Levy RL, Olden KW, Naliboff BD, et al Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology. 2006;130(5):1447–1458.
   PubMed Web of Science ®Google Scholar
• Spence MJ, Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut. 2007;56(8):1066–1071.
   PubMed Web of Science ®Google Scholar
• Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24–33.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503–3506.
   PubMed Web of Science ®Google Scholar
• Ford AC, Spiegel BMR, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–1286.
   PubMed Web of Science ®Google Scholar
• Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(4):535–544.
   PubMed Web of Science ®Google Scholar
• Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol. 2006;101(8):1894–1899.
   PubMed Web of Science ®Google Scholar
• Jalanka J, Salonen A, Fuentes S, et al. Microbial signatures in post-infectious irritable bowel syndrome - towards patient stratification for improved diagnostics and treatment. Gut Microbes. 2015;6(6):364–369.
   PubMedGoogle Scholar
• Simrén M, Barbara G, Flint HJ, et al Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–176.
   PubMed Web of Science ®Google Scholar
• Casén C, Vebø HC, Sekelja M, et al Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42(1):71–83.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–419.
   PubMed Web of Science ®Google Scholar
• Posserud I, Stotzer P-O, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802–808.
   PubMed Web of Science ®Google Scholar
• Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60(3):334–340.
   PubMed Web of Science ®Google Scholar
• Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57(5):1321–1329.
   PubMed Web of Science ®Google Scholar
• Johannesson E, Simrén M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915–922.
   PubMed Web of Science ®Google Scholar
• Ong DK, Mitchell SB, Barrett JS, et al Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25(8):1366–1373.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Quigley EMM, Lacy BE, et al The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367–1374.
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EMM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1350–1365. quiz 1366
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Spiegel BMR, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;(Nov 13):337. doi:10.1136/bmj.a2313.
   Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, et al Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329–341.
   PubMed Web of Science ®Google Scholar
• Quigley EMM, Tack J, Chey WD, et al Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013;37(1):49–61.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl):S2–26. quiz S27.
   PubMed Web of Science ®Google Scholar
• Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104(7):1831–1843. quiz 1844
   PubMed Web of Science ®Google Scholar
• Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol. 2006;101(5):1069–1079.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, et al Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2015;S0016-5085(15):01584–X. Nov 6 pii. doi:10.1053/j.gastro.2015.10.047. [Epub ahead of print].
   Google Scholar
• Matsueda K, Harasawa S, Hongo M, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion. 2008;77(3–4):225–235.
   PubMed Web of Science ®Google Scholar
• Garsed K, Chernova J, Hastings M, et al A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617–1625.
   PubMed Web of Science ®Google Scholar
• Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145(2):329–338. e1
   PubMed Web of Science ®Google Scholar
• Olafsdottir LB, Gudjonsson H, Jonsdottir HH, et al. Irritable bowel syndrome: physicians’ awareness and patients’ experience. World J Gastroenterol. 2012;18(28):3715–3720.
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EMM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–1561. quiz 1546, 1562
   PubMed Web of Science ®Google Scholar
• Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390–1397. e2
   PubMed Web of Science ®Google Scholar
• Jiang Q, Jiang X-H, Zheng M-H, et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2008;20(11):1064–1070.
   PubMed Web of Science ®Google Scholar
• Kimer N, Krag A, Møller S, et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014;40(2):123–132.
   PubMed Web of Science ®Google Scholar
• Alajbegovic S, Sanders JW, Atherly DE, et al. Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysis. Syst Rev. 2012;1:39.
   PubMedGoogle Scholar
• Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43(Suppl 1):27–36.
   PubMed Web of Science ®Google Scholar
• Huang H-F, Zeng Z, Wang K-H, et al. Heme oxygenase-1 protects rat liver against warm ischemia/reperfusion injury via TLR2/TLR4-triggered signaling pathways. World J Gastroenterol. 2015;21(10):2937–2948.
   PubMed Web of Science ®Google Scholar
• Cianci R, Frosali S, Pagliari D, et al Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin. J Immunol Res. 2014;2014:696812.
   PubMed Web of Science ®Google Scholar
• XIFAXAN. (Rifaximin) Tablets, 550 Mg, NDA 21–361: Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting. Gastrointestinal Drugs Advisory Committee. Department of Health & Human Services; U.S. Food and Drug Administration. 2011. [cited 2015 November]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/gastrointestinaldrugsadvisorycommittee/ucm279646.pdf
   Google Scholar
• Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers’ diarrhea. J Travel Med. 2001;8(Suppl s2):Ss34–9.
   Web of Science ®Google Scholar
• Drug information on XIFAXAN®. Salix pharmaceuticals. United States. 2015. [Cited 2015 November]. Available from: https://shared.salix.com/shared/pi/xifaxan550-pi.pdf
   Google Scholar
• Gillis JC, Brogden RN. Rifaximin A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49(3):467–484.
   PubMed Web of Science ®Google Scholar
• Compound summary for CID. 6436173 (Rifaximin). PubChem open chemistry database. Unites States National Library of Medicine, National Center for Biotechnology. United States. 2015. [Cited 2015 November]. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/Rifaximin#section=Top
   Google Scholar
• Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14(2):51–56.
   PubMedGoogle Scholar
• Darkoh C, Lichtenberger LM, Ajami N, et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 2010;54(9):3618–3624.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73(Suppl 1):13–27.
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44(8):2205–2206.
   PubMed Web of Science ®Google Scholar
• Taylor DN, McKenzie R, Durbin A, et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrobial Agents and Chemotherapy. 2008;52(3):1179–1181.
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Lupascu A, et al Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22(1):31–35.
   PubMed Web of Science ®Google Scholar
• Marchese A, Salerno A, Pesce A, et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy. 2000;46(4):253–266.
   PubMed Web of Science ®Google Scholar
• Pistiki A, Galani I, Pyleris E, et al. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43(3):236–241.
   PubMed Web of Science ®Google Scholar
• Jiang Z-D, Ke S, Dupont HL. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents. 2010;35(3):278–281.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Distrutti E, Mencarelli A, et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66(4):246–256.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Sanyal AJ, et al Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042.
   PubMed Web of Science ®Google Scholar
• DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther. 2016;43(Suppl 1):3–10.
   PubMed Web of Science ®Google Scholar
• Xu D, Gao J, Gillilland M, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484–496. e4
   PubMed Web of Science ®Google Scholar
• Brown EL, Xue Q, Jiang Z-D, et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother. 2010;54(1):388–396.
   PubMed Web of Science ®Google Scholar
• Cheng J, Shah YM, Ma X, et al Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010;335(1):32–41.
   PubMed Web of Science ®Google Scholar
• Terc J, Hansen A, Alston L, et al. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur J Pharm Sci. 2014;55:12–19.
   PubMed Web of Science ®Google Scholar
• Helwig U, Gionchetti P, Rizzello F, et al CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. Int J Colorectal Dis. 2004;19(2):165–170.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis E, Tang J, Pyleris E, et al Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50(9):1076–1087.
   PubMed Web of Science ®Google Scholar
• Huang JS, Jiang Z-D, Garey KW, et al. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013;57(6):2690–2693.
   PubMed Web of Science ®Google Scholar
• Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28–35. quiz 36.
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1–12.
   PubMed Web of Science ®Google Scholar
• Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy. 2007;27(10):1361–1369.
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Connolly M, Pentikis H, et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother. 2007;41(2):222–228.
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14(5):551–556.
   PubMed Web of Science ®Google Scholar
• Yang J, Lee H-R, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169–174.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557–563.
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326–333.
   PubMed Web of Science ®Google Scholar
• Lembo A, Zakko SF, Ferreira NL, et al T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134(4):A–545.
   Google Scholar
• Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol. 2011;4:43–48.
   PubMedGoogle Scholar
• Pimentel M, Lembo A, Chey WD, et al Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.
   PubMed Web of Science ®Google Scholar
• Irritable bowel syndrome with diarrhea (IBS-D) rifaximin re-treatment study (TARGET 3). NCT01543178. Valeant Pharmaceuticals International. United States, 2015. [Cited 2015 November]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01543178?sect=X70156&term=target+3&rank=1#outcome1
   Google Scholar
• Schoenfeld P, Pimentel M, Chang L, et al Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39(10):1161–1168.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Morales W, Chua K, et al Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci. 2011;56(7):2067–2072.
   PubMed Web of Science ®Google Scholar
• Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther. 2012;36(11–12):1084–1093.
   PubMed Web of Science ®Google Scholar